Merck KGaA (FRA:MRK) has been given a €108.00 ($125.58) price target by equities research analysts at Sanford C. Bernstein in a research report issued on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Sanford C. Bernstein’s target price indicates a potential upside of 17.21% from the stock’s current price.
Other equities analysts have also recently issued reports about the company. Kepler Capital Markets set a €108.00 ($125.58) target price on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, January 24th. UBS Group set a €115.00 ($133.72) price target on Merck KGaA and gave the company a “buy” rating in a research report on Thursday, March 7th. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the company a “buy” rating in a research report on Friday, March 8th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Merck KGaA in a research report on Tuesday, January 15th. Finally, Morgan Stanley set a €90.00 ($104.65) price target on Merck KGaA and gave the company a “neutral” rating in a research report on Monday, February 11th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the stock. Merck KGaA currently has an average rating of “Hold” and a consensus target price of €101.10 ($117.56).
Shares of MRK traded down €3.54 ($4.12) during mid-day trading on Tuesday, hitting €92.14 ($107.14). 885,044 shares of the company’s stock traded hands. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: Trading based on a resistance level
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.